J. Cummings

发表

Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.

R. L. Hayward, J. S. Macpherson, J. Cummings, 2004, Molecular cancer therapeutics.

[Arg6,D-Trp7,9,NmePhe8]-substance P (6–11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism

C. Haslett, J. Cummings, T. Sethi, 1999, British Journal of Cancer.

Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.

J. Cummings, J. Smyth, D. Jodrell, 2004, Biochemical pharmacology.

Tumorigenesis and Neoplastic Progression Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy

Caroline Dive, Lee Lancashire, Andrew Hughes, 2010 .

Fully phosphorothioated second-generation 19-mer mixed-backbone antisense oligonucleotide (ASO) consisting of an 11-nucleotide DNA core flanked at the 3' and 5' ends by four 2'-O-methyl RNA residues, targeting the X-linked inhibitor of apoptosis protein (XIAP)

M. Ranson, T. Ward, C. Dive, 2009 .

Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

M. Ranson, T. Ward, C. Dive, 2005, British Journal of Cancer.

DNA damage is able to induce senescence in tumor cells in vitro and in vivo.

S. Joel, A. Okorokov, J. Cummings, 2002, Cancer research.

Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells

N. Clarke, C. Dive, J. Cummings, 2014, BMC Cancer.

Method validation of circulating tumour cell enumeration at low cell counts

C. Dive, J. Cummings, M. Krebs, 2013, BMC Cancer.

The effect of verapamil on the pharmacokinetics of adriamycin

D. Kerr, M. Brodie, S. Kaye, 2004, Cancer Chemotherapy and Pharmacology.

Circulating Biomarkers of Cell Death After Treatment with the BH-3 Mimetic ABT-737 in a Preclinical Model of Small-Cell Lung Cancer

T. Ward, C. Dive, D. Micha, 2008, Clinical Cancer Research.

Inhibition of cancer cell growth by ruthenium(II) arene complexes.

J. Cummings, R. Aird, P. Sadler, 2001, Journal of medicinal chemistry.

Biomarkers of apoptosis

J Cummings, M. Ranson, T. Ward, 2008, British Journal of Cancer.

The role of protein kinase C and the phosphatidylinositol cycle in multidrug resistance in human ovarian cancer cells.

J. Cummings, J. Smyth, T. Bradshaw, 1991, Biochemical pharmacology.

Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography

J. S. Macpherson, J. Cummings, J. Smyth, 2004, Cancer Chemotherapy and Pharmacology.

'Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use.

G. Jayson, T. Ward, C. Dive, 2009, Journal of immunological methods.

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

T. Ward, C. Dive, J. Cummings, 2012, British Journal of Cancer.

Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1.

L. Aarons, M. Ranson, T. Ward, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.

M. Berger, M. Ranson, A. Roulston, 2011, Neoplasia.

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma

J. Radford, M. Ranson, T. Ward, 2011, British Journal of Cancer.

Antagonists of mitogenic peptides.

J. Cummings, J. Smyth, S. Langdon, 1994 .

Fit-for-purpose biomarker method validation in anticancer drug development.

T. Ward, C. Dive, J. Cummings, 2010, Drug discovery today.

Pharmacokinetics of high molecular weight agents.

S. Wedge, D. Newell, J. Cummings, 1993, Cancer surveys.

Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg6,D-Trp7,9,NmePhe8]-substance P (6–11)-induced growth inhibition

C. Haslett, J. Cummings, D. Jodrell, 2003, British Journal of Cancer.

substance P (6 -11)-induced growth inhibition

C. Haslett, J. Cummings, D. Jodrell, 2003 .

Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug.

C. McArdle, J. Cummings, J. Cummings, 1986, British Journal of Cancer.

Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development.

M. Tomasz, J. Cummings, J. Smyth, 1998, Biochemical pharmacology.

Mitomycin C-DNA adducts generated by DT-diaphorase. Revised mechanism of the enzymatic reductive activation of mitomycin C.

M. Tomasz, J. Cummings, R. Lipman, 1997, Biochemistry.

Microspheres as a drug delivery system in cancer therapy

J. Cummings, 1998 .

The role of reductive enzymes in cancer cell resistance to mitomycin C.

J. Cummings, 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.

Stephen J. Morris, L. Aarons, M. Ranson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon.

J. Cummings, B. Burchell, L. Jardine, 2006, Anticancer research.

5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer

J. Cummings, R. Aird, L. Wall, 2001, British Journal of Cancer.

Comparative cardiotoxicity and antitumour activity of doxorubicin (adriamycin) and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues.

D. Kerr, S. Kaye, J. Cummings, 1987, Biochemical pharmacology.

Marked inter-patient variation in adriamycin biotransformation to 7-deoxyaglycones: evidence from metabolites identified in serum.

D. Cunningham, S. Kaye, J. Cummings, 1986, European journal of cancer & clinical oncology.

In vitro release of adriamycin from drug-loaded albumin and haemoglobin microspheres.

J. Cummings, A. Florence, N. Willmott, 1985, Journal of microencapsulation.

Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects.

T. Ward, T. Illidge, M. Cragg, 2010, Journal of immunological methods.

Doxorubicin‐loaded Casein Microspheres: Protean Nature of Drug Incorporation

J. Cummings, J. Smyth, G. Halbert, 1992, The Journal of pharmacy and pharmacology.

Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.

J. S. Macpherson, J. Cummings, J. Smyth, 2002, Biochemical pharmacology.

Factors influencing the cellular accumulation of SN-38 and camptothecin

Gillian Smith, J. S. Macpherson, J. Cummings, 2002, Cancer Chemotherapy and Pharmacology.

Optimisation of circulating biomarkers of cell death for routine clinical use.

M. Ranson, T. Ward, C. Dive, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Determination of the glucuronide metabolites of the topoisomerase I inhibitors 7-Ethyl 10-hydroxycamptothecin (SN-38) and NU/ICRF 505 by high-performance liquid chromatography

J. Cummings, J. Smyth, D. Jodrell, 2002 .

Disposition kinetics of adriamycin, adriamycinol and their 7-deoxyaglycones in AKR mice bearing a sub-cutaneously growing ridgway osteogenic sarcoma (ROS).

J. Cummings, N. Willmott, S. Merry, 1986, European journal of cancer & clinical oncology.

Method for the determination of 4-Demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography

S. Kaye, J. Cummings, R. Milroy, 2004, Cancer Chemotherapy and Pharmacology.

Occurrence of circulating 7-deoxyaglycone metabolites of 4′-deoxydoxorubicin in man

D. Kerr, S. Kaye, J. Cummings, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacology of adriamycin: the message to the clinician.

J. Cummings, J. Smyth, 1988, European journal of cancer & clinical oncology.

Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.

K. Calman, J. Cummings, J. Stuart, 1984, Journal of chromatography.

Etoposide: A pharmacokinetic profile including an assessment of bioavailability

D. Cunningham, J. Cummings, J. Stuart, 1986, Medical oncology and tumor pharmacotherapy.

The pharmacokinetics of high dose cyclophosphamide and high dose etoposide

D. Cunningham, S. Kaye, J. Cummings, 1988, Medical oncology and tumor pharmacotherapy.

How much does liver disease affect the pharmacokinetics of adriamycin?

D. Kerr, S. Kaye, J. Cummings, 1985, European journal of cancer & clinical oncology.

Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice.

D. Kerr, J. Double, M. Bibby, 1989, Cancer research.

Daunorubicin cardiotoxicity in childhood cancer

J. Cummings, P. Shaw, L. Samuel, 1998, The Lancet.

Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates.

J. S. Macpherson, J. Cummings, J. Smyth, 1995, Biochemical pharmacology.

Explorer 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer

J. Cummings, R. Aird, L. Wall, 2001 .

The consequences of doxorubicin quinone reduction in vivo in tumour tissue.

J. Cummings, J. Smyth, J. F. Smyth, 1992, Biochemical pharmacology.

Determination of reactive nitrogen mustard anticancer drugs in plasma by high-performance liquid chromatography using derivatization.

J. Cummings, J. Smyth, P. Farmer, 1991, Analytical chemistry.

Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.

J. S. Macpherson, J. Cummings, J. Smyth, 1996, British Journal of Cancer.

Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500.

J. S. Macpherson, J. Cummings, J. Smyth, 1995, Mutation research.

Pharmacological determinants of the antitumour activity of mitomycin C.

J. Cummings, J. Smyth, V. Spanswick, 1998, Biochemical pharmacology.

Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography.

J. S. Macpherson, J. Cummings, J. Smyth, 1996, Journal of chromatography. B, Biomedical applications.

Development of a gradient elution high-performance liquid chromatography assay with ultraviolet detection for the determination in plasma of the anticancer peptide [Arg6, D-Trp7,9, mePhe8]-substance P (6-11) (antagonist G), its major metabolites and a C-terminal pyrene-labelled conjugate.

J. Cummings, D. Jodrell, M. Mark, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours

J. Cummings, J. Smyth, 2004, Cancer Chemotherapy and Pharmacology.

Adriamycin-loaded niosomes: drug entrapment, stability and release.

J. Cummings, A. Florence, A. Rogerson, 1987, Journal of microencapsulation.

In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

J. Cummings, R. Aird, P. Sadler, 2002, British Journal of Cancer.

The autoxidation of the reduced forms of EO9.

J. Cummings, V. Spanswick, J. Butler, 1996, Free radical research.

DNA topoisomerase I and II as targets for rational design of new anticancer drugs.

J. Cummings, J. Smyth, Jeffrey Cummings, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

The Distribution of Doxorubicin in Mice Following Administration in Niosomes

J. Cummings, A. Florence, N. Willmott, 1988, The Journal of pharmacy and pharmacology.

Application of the β-expectation tolerance interval to method validation of the M30 and M65 ELISA cell death biomarker assays.

Jeffrey Cummings, Caroline Dive, C. Dive, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

Naveena Singh, P. Chakravarty, K. Jirström, 2011, Clinical Cancer Research.

Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs.

J. S. Macpherson, J. Cummings, J. Smyth, 1995, Anti-cancer drug design.

Biomarker method validation in anticancer drug development

J Cummings, M. Ranson, T. Ward, 2008, British journal of pharmacology.

Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

G. Jayson, M. Ranson, C. Dive, 2006, British Journal of Cancer.

Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity

T. Ward, C. Dive, J. Cummings, 2008, Molecular Cancer Therapeutics.

Preclinical evaluation of M 30 and M 65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity

T. Ward, C. Dive, J. Cummings, 2008 .

2,7-Diaminomitosene, a Monofunctional Mitomycin-C Derivative, Alkylates DNA in the Major Groove - Structure and Base-Sequence Specificity of the DNA Adduct and Mechanism of the Alkylation

M. Tomasz, J. Cummings, S. Musser, 1996 .

2,7-Diaminomitosene (I), a Monofunctional Mitomycin C Derivative, Alkylates DNA in the Major Groove. Structure and Base-Sequence Specificity of the DNA Adduct and Mechanism of the Alkylation.

M. Tomasz, J. Cummings, S. Musser, 1997 .

Determination of mitomycin C, 2,7-diaminomitosene, 1,2-cis- and 1,2-trans-1-hydroxy-2,7-diaminomitosene in tumour tissue by high-performance liquid chromatography.

J. Cummings, J. Smyth, G. Halbert, 1993, Journal of Chromatography A.

Enzymology of mitomycin C metabolic activation in tumour tissue. Characterization of a novel mitochondrial reductase.

J. Cummings, J. Smyth, V. Spanswick, 1996, Biochemical pharmacology.

Re-evaluation of the molecular pharmacology of mitomycin C.

J. Cummings, J. Smyth, V. Spanswick, 1995, European journal of cancer.

Conversion of mitomycin C to 2,7-diaminomitosene and 10-decarbamoyl 2,7-diaminomitosene in tumour tissue in vivo

J. Cummings, J. Smyth, G. Halbert, 1995, Cancer Chemotherapy and Pharmacology.

Current issues in the enzymology of mitomycin C metabolic activation.

J. Cummings, J. Smyth, V. Spanswick, 1998, General pharmacology.

Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinone reduction in tumour tissue and antitumour activity. Implications for the drugs' in vivo mechanism of action.

J. Cummings, J. Smyth, L. Allan, 1994, Biochemical pharmacology.

Incorporation and release of chemically intact mitomycin C from albumin microspheres: a high performance liquid chromatography evaluation.

J. Cummings, J. Smyth, N. Willmott, 1993, Journal of drug targeting.

Application of high-performance liquid chromatography for recognition of covalent nucleic acid modification with anticancer drugs.

J. Cummings, J. Smyth, R. French, 1993, Journal of chromatography.

A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours

A. Harris, G. Parker, G. Jayson, 2013, Cancer Chemotherapy and Pharmacology.

Serum Biomarkers of Apoptosis

M. Ranson, T. Ward, C. Dive, 2007 .

Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.

R. L. Hayward, J. S. Macpherson, J. Cummings, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Apoptosis pathway-targeted drugs--from the bench to the clinic.

M. Ranson, T. Ward, C. Dive, 2004, Biochimica et biophysica acta.

Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

J Cummings, C. Dive, J. Cummings, 2010, British Journal of Cancer.

The molecular pharmacology of doxorubicin in vivo.

J. Cummings, J. Smyth, N. Willmott, 1991, European journal of cancer.

Cancer Therapy : Clinical Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer

P. Chakravarty, I. McNeish, N. Avril, 2011 .

Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice.

D. Burns, J. Cummings, S. Langdon, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmaceutical analysis of 8-chloroadenosine 3',5'-monophosphate.

J. Cummings, W. Miller, H. Fielding, 1994, Journal of pharmaceutical and biomedical analysis.

Sensitive determination of 8-chloroadenosine 3',5'-monophosphate and 8-chloroadenosine in plasma by high-performance liquid chromatography.

J. Cummings, R. Leonard, W. Miller, 1994, Journal of chromatography. B, Biomedical applications.

Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.

Jeffrey Cummings, John F Smyth, J. S. Macpherson, 2003, Cancer research.

Preclinical Evaluation of the Pharmacodynamic Properties of 2,5-Diaziridinyl-3-Hydroxymethyl-6-Methyl-1,4-Benzoquinone

G. Jayson, M. Ranson, T. Ward, 2005, Clinical Cancer Research.

Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients

D. Cunningham, J. Cummings, G. Forrest, 2004, Cancer Chemotherapy and Pharmacology.

Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells

C. Dive, J. Cummings, K. Morris, 2015, BMC Cancer.

The review presents strategies for fit-for-purpose method validation of biomarker assays to help ensure generation of robust data during clinical trials and to satisfy regulatory requirements. Fit-for-purpose biomarker method validation inanticancerdrugdevelopment

Jeffrey Cummings, Caroline Dive, Jeffrey L. Cummings, 2010 .

Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.

E. D. de Vries, S. de Jong, L. Lancashire, 2008, Neoplasia.

Effect of human recombinant interferon-alpha on the activity of cis-diamminedichloroplatinum(II) in human non-small cell lung cancer xenografts.

J. Cummings, J. Smyth, A. Ritchie, 1995, Cancer investigation.

Increases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo.

C. Dive, J. Cummings, C. Cawthorne, 2006, Neoplasia.

Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activity.

J. Cummings, J. Smyth, N. Willmott, 1990, Biochemical Pharmacology.

Chapter 2 – Cytotoxic drug delivery

J. Cummings, J. Smyth, 1993 .

Adriamycin-loaded albumin microspheres: preparation, in vivo distribution and release in the rat.

J Cummings, A T Florence, J. Cummings, 1985, Biopharmaceutics & drug disposition.

Correlation between tumour drug disposition and the antitumour activity of doxorubicin-loaded microspheres: implications for the drugs' in vivo mechanism of action.

J. Cummings, J. Smyth, N. Willmott, 1993, Biochemical pharmacology.

Covalent coupling of doxorubicin in protein microspheres is a major determinant of tumour drug disposition.

J. Cummings, J. Smyth, N. Willmott, 1991, Biochemical pharmacology.

Determination of covalent binding to intact DNA, RNA, and oligonucleotides by intercalating anticancer drugs using high-performance liquid chromatography. Studies with doxorubicin and NADPH cytochrome P-450 reductase.

A. Bartoszek, J. Cummings, J. Smyth, 1991, Analytical biochemistry.

Increased anti-tumor effect of adriamycin-loaded albumin microspheres is associated with anaerobic bioreduction of drug in tumor tissue.

J. Cummings, N. Willmott, 1987, Biochemical pharmacology.

Adriamycin-loaded albumin microspheres: qualitative assessment of drug incorporation and in vitro release by high-performance liquid chromatography and high-speed multi-diode array spectrophotometric detection.

J. Cummings, N. Willmott, 1985, Journal of chromatography.

Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance.

J. S. Macpherson, J. Cummings, J. Smyth, 1996, Biochemical pharmacology.

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours

J. Cummings, J. Dixon, W. Miller, 2000, British Journal of Cancer.

Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in breast tumour tissues.

J. Cummings, J. Dixon, W. Miller, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma

M. Ranson, C. Dive, J. Cummings, 2007, Cancer Chemotherapy and Pharmacology.

High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells.

J. Cummings, J. Smyth, D. Jodrell, 2001, Analytical biochemistry.

Cell cycle effects of the novel topoisomerase I inhibitor NU/ICRF 505 in a panel of Chinese hamster ovary cell lines.

J. S. Macpherson, J. Cummings, J. Smyth, 1997, European journal of cancer.

Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer

S. Kaye, J. Cummings, R. Milroy, 2004, Cancer Chemotherapy and Pharmacology.

The enzymology of doxorubicin quinone reduction in tumour tissue.

P. Workman, J. Cummings, J. Smyth, 1992, Biochemical pharmacology.

Studies on the molecular pharmacology of GR63178A. A novel pentacyclic pyrolloquinone anticancer drug.

I. Hickson, J. Cummings, J. Smyth, 1992, Biochemical pharmacology.

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer

M. Ranson, C. Dive, J. Cummings, 2012, British Journal of Cancer.

Determination of anthracycline purity in patient samples and identification of in vitro chemical reduction products by application of a multi-diode array high-speed spectrophotometric detector.

J. Cummings, N. Willmott, J. Morrison, 1986, Journal of chromatography.

Method for the determination of 4'-deoxydoxorubicin, 4'-deoxydoxorubicinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography.

J. Cummings, 1985, Journal of chromatography.

Molecular modeling of the interaction of anthracenyl-amino acid topoisomerase inhibitors with the DNA sequence d(CGTACG)

J. Cummings, J. Smyth, A. McGown, 1996, Anti-cancer drugs.

Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9.

J. Cummings, J. Smyth, V. Spanswick, 1998, Biochemical pharmacology.

Clinical Evaluation of M 30 and M 65 ELISA Cell Death Assays as Circulating Biomarkers in a Drug-Sensitive Tumor , Testicular Cancer 1

L. Lancashire, C. Dive, J. Cummings, 2008 .

Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology

S. Kaye, J. Cummings, J. Smyth, 2004, Cancer Chemotherapy and Pharmacology.

The comparative disposition of the pyrolloquinone GR63178A and its 9-hydroxy metabolite GR54374X in sensitive and resistant mouse colon adenocarcinoma

J. S. Macpherson, J. Cummings, J. Smyth, 2004, Cancer Chemotherapy and Pharmacology.

Chromatographic characterisation of six human metabolites of the new anticancer drug GR63 178A

J. Cummings, J. Smyth, A. MacLellan, 2004, Cancer Chemotherapy and Pharmacology.

Stability of GR63178A, a Novel Pentacyclic Pyrroloquinone Anticancer Compound, in Aqueous Solutions and Biological Fluids

J. Cummings, J. Smyth, R. French, 1993, The Journal of pharmacy and pharmacology.

A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors.

M. Ranson, T. Ward, C. Dive, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of a subcutaneously growing Walker 256 carcinosarcoma on host tissue mitochondrial function and magnesium content.

K. Calman, J. Cummings, N. Willmott, 1984, Cancer research.

Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.

P. Lorigan, C. Dive, J. Cummings, 2013, The Journal of investigative dermatology.

Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma.

J. Cummings, J. Dixon, W. Miller, 1996, Journal of chromatography. B, Biomedical applications.

Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial

M. Ranson, T. Ward, J. Cummings, 2007, Cancer Chemotherapy and Pharmacology.

Rapid and selective isolation of radiolabelled inositol phosphates from cancer cells using solid-phase extraction.

J. Cummings, J. Smyth, L. Anderson, 1992, Journal of Chromatography A.

The effect of adrenalectomy upon the absorption, distribution and metabolism of ethanol in the rat.

G. Powis, J. Cummings, E. Morgan, 1977, Life sciences.

Pharmacokinetics, Bioavailability, Metabolism, Tissue Distribution and Urinary Excretion of γ‐L‐Glutamyl‐L‐dopa in the Rat

J. Cummings, J. Smyth, L. M. Matheson, 1990, The Journal of pharmacy and pharmacology.

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs

G. Jayson, T. Ward, C. Dive, 2010, British Journal of Cancer.

Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells

N. Clarke, C. Dive, J. Cummings, 2014, BMC Cancer.

Quantitative analysis of biomarkers by LC-MS/MS.

T. Veenstra, J. Cummings, R. Unwin, 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.

C. Dive, J. Cummings, F. Raynaud, 2010 .

[Arg6,D-Trp7,9,NmePhe8]-substance P (6–11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism

C. Haslett, J. Cummings, T. Sethi, 1999, British Journal of Cancer.

Increased gastrin-releasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg6,D-Trp7,9,NmePhe8]-substance P (6–11)-induced growth inhibition

C. Haslett, J. Cummings, D. Jodrell, 2003, British Journal of Cancer.

Optimisation of a reversed-phase high-performance liquid chromatographic method for the determination of flavone acetic acid and its major human metabolites in plasma and urine.

S. Kaye, J. Cummings, J. Smyth, 1988, Journal of chromatography.

Method for the determination of γ-l-glutamyl-l-dihydroxyphenylalanine and its major metabolites l-dihydroxyphenylalanine, dopamine and 3,4-dihydroxyphenylacetic acid by high-performance liquid chromatography with electrochemical detection

J. Cummings, J. Smyth, L. M. Matheson, 1990 .

Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells

C. Dive, J. Cummings, K. Morris, 2015, BMC Cancer.